Literature DB >> 9095107

Resuscitation from hemorrhagic shock with diaspirin cross-linked hemoglobin, blood, or hetastarch.

D A DeAngeles1, A M Scott, A M McGrath, V A Korent, L A Rodenkirch, R L Conhaim, B A Harms.   

Abstract

BACKGROUND: An oxygen-transporting hemoglobin solution should be more effective than a nonhemoglobin solution for resuscitation from hemorrhagic shock. A way to evaluate this effectiveness is to determine whether a hemoglobin solution can reverse the base deficit accumulated during hemorrhage at a faster rate than a nonhemoglobin solution. Using this criterion, we compared the resuscitative powers of autologous blood, hetastarch (Het), and diaspirin cross-linked hemoglobin (DCLHb).
METHODS: Fifteen sedated, spontaneously breathing sheep (37.5 +/- 10.2 kg) were bled until base deficits fell to -5 to -10 mEq/L, and plasma lactate concentrations rose to 6 to 9 mg/L. The animals were resuscitated with autologous blood (n = 5), Het (n = 5), or DCLHb (n = 5) (3.5-4.0 mL/kg every 15 minutes) until base deficits returned to prehemorrhage baseline.
RESULTS: Exsanguination to target base deficits required removal of an average of 41.4 +/- 5.5 mL blood/kg (estimated total blood volume, 80 mL/kg). Resuscitation required 18 +/- 3, 38 +/- 2 (different from blood), and 35 +/- 1 (different from blood) mL/kg of autologous blood, Het and DCLHb, respectively, over periods of 78 +/- 8, 163 +/- 10 (different from blood), and 129 +/- 9 minutes (different from blood and different from Het (p < or = 0.05)). Based on regression analysis, autologous blood, Het, and DCLHb corrected the base deficit at rates of, respectively, 0.074 (different from Het (p < or = 0.05)), 0.016, and 0.056 (different from Het (P < or = 0.05)) mEq/L/min.
CONCLUSIONS: Based on the rate of base deficit correction and the volume of solution required, autologous blood was the most effective resuscitation solution. However, DCLHb was more effective than Het. DCLHb may be an attractive alternative to blood for resuscitation from hemorrhagic shock.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9095107     DOI: 10.1097/00005373-199703000-00007

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  5 in total

1.  The clinical trials of diaspirin cross-linked hemoglobin (DCLHb) in severe traumatic hemorrhagic shock: the tale of two continents.

Authors:  Edward P Sloan
Journal:  Intensive Care Med       Date:  2003-03       Impact factor: 17.440

2.  Polynitroxylated-pegylated hemoglobin attenuates fluid requirements and brain edema in combined traumatic brain injury plus hemorrhagic shock in mice.

Authors:  Erik C Brockman; Hülya Bayır; Brian Blasiole; Steven L Shein; Ericka L Fink; Cedward Dixon; Robert S B Clark; Vincent A Vagni; Li Ma; Carleton J C Hsia; Samuel A Tisherman; Patrick M Kochanek
Journal:  J Cereb Blood Flow Metab       Date:  2013-06-26       Impact factor: 6.200

3.  DCL-Hb for trauma patients with severe hemorrhagic shock: the European "On-Scene" multicenter study.

Authors:  Thoralf Kerner; Olaf Ahlers; Siegfried Veit; Bruno Riou; Michael Saunders; Ulrich Pison
Journal:  Intensive Care Med       Date:  2003-01-23       Impact factor: 17.440

Review 4.  Bench-to-bedside review: oxygen debt and its metabolic correlates as quantifiers of the severity of hemorrhagic and post-traumatic shock.

Authors:  Dieter Rixen; John H Siegel
Journal:  Crit Care       Date:  2005-04-20       Impact factor: 9.097

Review 5.  Blood substitutes. Haemoglobin therapeutics in clinical practice.

Authors:  J F Baron
Journal:  Crit Care       Date:  1999-09-28       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.